NewAmsterdam Pharma Co N.V.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No N-PORT holders.
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Frazier Life Sciences ManagementFrazier Life Sciences | $613.0M | 14.55% | +6.76% | |
| 2 | Capital World InvestorsCapital World Investors | $414.5M | 9.84% | +10.10% | |
| 3 | FMRFMR | $350.4M | 8.32% | +17.95% | |
| 4 | RA Capital ManagementRA Capital Management | $323.7M | 7.68% | 0.00% | |
| 5 | Fcpm III Services B.V.Fcpm III Services B.V. | $287.7M | 6.83% | −7.70% | |
| 6 | Deerfield ManagementDeerfield | $144.5M | 3.43% | 0.00% | |
| 7 | Viking Global InvestorsViking Global Investors | $142.5M | 3.38% | 0.00% | |
| 8 | Bain Capital Life Sciences InvestorsBain Capital Life Sciences Investors | $129.0M | 3.06% | −47.90% | |
| 9 | Maverick CapitalMaverick Capital | $110.7M | 2.63% | +49.46% | |
| 10 | Duquesne Family OfficeDuquesne Family Office | $104.0M | 2.47% | 0.00% | |
| 11 | Jupiter TopcoJupiter Topco | $86.0M | 2.04% | — | |
| 12 | Medicxi Ventures Management (Jersey)Medicxi Ventures Management (Jersey) | $74.9M | 1.78% | −17.41% | |
| 13 | Jennison AssociatesJennison | $71.2M | 1.69% | −23.56% | |
| 14 | Orbis Allan GrayOrbis Allan Gray | $59.2M | 1.41% | new | |
| 15 | Polar Capital HoldingsPolar Capital | $58.4M | 1.39% | −39.10% | |
| 16 | Capital International InvestorsCapital International Investors | $58.4M | 1.39% | +19.59% | |
| 17 | Goldman Sachs GroupGoldman Sachs | $52.9M | 1.26% | −19.75% | |
| 18 | Westfield Capital ManagementWestfield | $52.1M | 1.24% | −30.25% | |
| 19 | Susquehanna International GroupSusquehanna International | $49.8M | 1.18% | +216.04% | |
| 20 | Castle Hook PartnersCastle Hook Partners | $46.5M | 1.10% | +31.49% | |
| 21 | Ameriprise FinancialAmeriprise Financial | $42.5M | 1.01% | +66.46% | |
| 22 | AlliancebernsteinAlliancebernstein | $40.3M | 0.96% | +5.05% | |
| 23 | T. Rowe Price AssociatesT. Rowe Price | $39.6M | 0.94% | new | |
| 24 | JPMorgan ChaseJPMorgan Chase | $38.4M | 0.91% | +28.13% | |
| 25 | Standard Life AberdeenStandard Life Aberdeen | $37.4M | 0.89% | +31.75% |
195 managers report $4.2B of NewAmsterdam Pharma on form 13F for the quarter ended Jun 30 '26. 24 of them hold 80% of it; Frazier Life Sciences is largest at 14.55%.
NewAmsterdam Pharma Co N.V.
20.05
−0.71 · −3.42%
post 20.05 0.00%
Expected move
Inputsstraddle ±13.7%
spot 20.06exp Nov 20ATM strike 20ATM straddle 3.22IV 83%